

# **Effect of on-line hemodiafiltration on serum tumor necrosis factor in pediatric hemodialysis patients**

Thesis

For partial fulfillment of MSc degree in Pediatrics

**By**

**Eman Abobaker Abd Alazim**

**Supervisors**

**Prof. Mohammed Hesham Safouh**

Professor of Pediatrics

Faculty of Medicine – Cairo University

**Ass.Prof. Hafez Mahmoud Bazaraa**

Assistant Professor of Pediatrics

Faculty of Medicine – Cairo University

**Ass.Prof.Hanan Ali Madani**

Assistant Professor of Clinical and Chemical Pathology

Faculty of Medicine – Cairo University

**Department of pediatrics**

**Faculty of Medicine**

**Cairo University**

**2012**

---

## *Acknowledgments*

First of all, I thank **ALLAH** to whom I relate any success I have reached & might reach in the future.

I am greatly honored to express my sincere gratitude & appreciation to **Dr. Mohammed Hesham Safouh**, Professor of Pediatrics, Faculty of Medicine, Cairo University for his meticulous supervision, loyal encouragement & valuable advice throughout the work.

Also, I would like to express my deepest appreciation to **Dr. Hafez Mahmoud Bazaraa**, Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University for his remarkable suggestions & close supervision, which were behind the fruitful outcome of all this work.

I would like to express my deepest thanks to **Dr. Hanan Ali Madani**, Assistant Professor of Chemical Pathology, Faculty of Medicine, Cairo University for her meticulous and remarkable work in the laboratory part of this work.

Last but not the least, I am deeply thankful and always indebted to my parents and my brothers *Mohamed & Ehab* who were always supporting and encouraging me.

---

# **Abstract**

**Background:** Hemodiafiltration (HDF) is a form of renal replacement therapy. Tumor necrosis factor (TNF) is proinflammatory cytokine and has been reported to be elevated in adults with ESRD on hemodialysis.

**Objective:** To compare TNF levels and dialytic change between conventional hemodialysis and on-line hemodiafiltration.

**Methods** The study included 2 groups of pediatric patients (<15 years of age) with ESRD; group I (n=16) treated with on-line HDF and group II (n=20) with conventional low-flux hemodialysis. Plasma TNF was measured for all patients at the beginning and termination of a dialysis session.

**Results:** TNF levels in patients treated with online HDF (106.2 +/- 57.5 pg/mL) were lower than in those on conventional HD (180.5 +/- 71.7 pg/mL); p=0.002.

Both groups had significantly higher levels than controls. Post-dialysis values were 82.1 +/- 36.1 pg/mL and 179.1 +/- 83.5 for HDF and HD respectively, both reflecting insignificant reductions (p=0.17 & 0.98).

**Conclusion:** In children with ESRD, online HDF is associated with lower plasma concentrations of proinflammatory cytokines (as TNF) than conventional HD.

**Key words:** cytokines–ESRD –hemodialysis-online HDF.

# Contents

Subjects	Page
<b>Abstract</b> .....	II
<b>Abbreviations</b> .....	IV
<b>List of tables</b> .....	VII
<b>List of figures</b> .....	VIII
<b>Introduction and aim of the work</b> .....	1-3
<b>Review of literature</b> .....	4-46
Chapter (1): ESRD .....	4-25
Chapter (2): online-hemodiafiltration .....	26-35
Chapter (3): tumor necrosis factor alpha .....	36-46
<b>Patients and methods</b> .....	47-52
<b>Results</b> .....	53-64
<b>Discussion</b> .....	65-70
<b>Summary and conclusions</b> .....	71-73
<b>Recommendations</b> .....	74
<b>References</b> .....	75-103
<b>Arabic summary</b> .....	104

## **Abbreviation**

- AAMI: Advancement of Medical Instrumentation.
- ACE: Angiotensin-converting enzyme.
- AFB: acetate-free biofiltration.
- APRIL: proliferation-inducing ligand.
- AVF: Arteriovenous fistula.
- AVG: Arteriovenous graft.
- BAFF-R: B-cell activating factor family receptor.
- BCMA: -cell maturation antigen.
- BUN: blood urea nitrogen.
- Ca P: calcium phosphorous product.
- Ca: calcium.
- CFU: colony forming units.
- CKD: Chronic kidney disease.
- CRDs: cysteine-rich domains.
- CRH: corticotropin releasing hormone.
- CRP: C-reactive protein.
- $C_{UF}$ : ultrafiltration coefficient.
- DBP: diastolic blood pressure.
- DOPPS: Dialysis Outcomes and Practice Patterns Study.
- ECD: extracellular domain.
- eGFR: estimated glomerular filtration rate.
- ESA: erythropoiesis stimulating agents.

- ESRD: End-stage renal disease.
- ELISA: enzyme linked immunosorbent assay.
- EU: Endotoxin Units.
- GFR: Glomerular filtration rate.
- HB: hemoglobin.
- HDF: Hemodiafiltration.
- HF: Hemofiltration.
- ICD: intracellular domain.
- IRS-1: insulin receptor substrate-1.
- K/DOQI: Kidney Disease Outcomes Quality Initiative.
- $Kt/V$ : dialyzer urea clearance ( $K$ ) per unit time ( $t$ ) of the dialysis session divided by urea volume ( $V$ ) of distribution.
- LAK : lymphocyte-activated killer.
- LT: lymphotoxin ( $LT\alpha$ ,  $LT\beta$ ).
- LVMI: left ventricular mass index.
- NK: natural killer.
- PDUR: postdialytic urea rebound.
- PGE2: prostaglandin E2.
- PKC: protein kinase C.
- PLT: platelets.
- PO4: phosphorous.
- PTFE: polytetrafluoroethylene.
- QOL: quality of life.
- RDA: recommended daily amounts.
- SBP: systolic blood pressure.
- SIRS: Systemic Inflammatory Response Syndrome.

- sTNFR: soluble form of TNF receptors.
- TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor.
- TIBC: total iron binding capacity.
- TLC: Total leucocytic count.
- TMD: transmembrane domain.
- TMP: transmembrane pressure.
- TNF: Tumor necrosis factor.
- TNFR: tumor necrosis factor receptor.
- TNFR1: TNF-receptor type 1.
- TNFR2: TNF-receptor type 2.
- TNFRSF: Tumor necrosis factor receptor superfamily.
- TSAT: transferrin saturation.
- UF: ultrafiltration
- UKM: Urea kinetic modeling
- USRDS: The United States Renal Data System
- VSMCs: vascular smooth muscle cells
- VUR: Vesicoureteric reflux

## **List of Tables**

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table (1)	Stages of CKD (National Kidney Foundation classification of chronic kidney disease)	5
Table (2)	Composition of a standard hemodialysis solution	21
Table (3)	Functional role of TNF mediated through TNFR-1 and TNFR-2	44
Table (4)	comparison between the two study groups as regards the original disease	55
Table (5)	comparison between HDF and HD as regard age, duration of dialysis and anthropometric measure	55
Table (6)	comparison between the two study groups as regards associated co-morbidities	57
Table (7)	comparison between the two study groups as regard systolic and diastolic blood pressure before and after a dialysis session	58
Table (8)	comparison between the two study groups in baseline routine laboratory investigations	59
Table (9)	TNF level in children with ESRD compared to controls.	60
Table (10)	comparison of serum TNF levels between both study groups	60
Table (11)	correlation between TNF levels (before & after dialysis session) and age, anthropometric measures & duration of dialysis	61
Table (12)	correlation between TNF level before and after dialysis session & blood pressure in the two study groups	61
Table (13)	correlation between the TNF level and other laboratory parameters	64



## List of figures

<b>Figure No.</b>	<b>Title</b>	<b>page</b>
Fig. (1)	hemodialysis circuit	18
Fig. (2)	TNF $\alpha$ molecule	37
Fig. (3): A.	Schematic representation of the location of tumor necrosis factor (TNF) cluster in the major histocompatibility complex on chromosome 6	38
Fig. (3): B.	Schematic representation of gene structure of TNF $\alpha$ , LT $\beta$ and LT $\alpha$ with direction of transcription followed by single nucleotide polymorphism	38
Fig. (4)	modality of hemodialysis among the study group	53
Fig. (5)	sex distribution among the study group	53
Fig. (6)	original renal disease distribution among the study group	54
Fig. (7)	associated co-morbidities among the study group	56
Fig. (8)	Comparison between the two study groups as regards associated anemia	57
Fig. (9)	comparison between the two study groups as regards total leucocytic count (TLC)	59
Fig. (10)	comparison between serum TNF level before & after dialysis session in both study groups	60
Fig. (11)	correlation between the systolic blood pressure before the start of dialysis session and TNF level at the end of dialysis session on HD	62
Fig. (12)	correlation between the diastolic blood pressure before the start of dialysis session and TNF level at the end of dialysis session on HD	63

## **Introduction**

Chronic kidney disease (CKD) is an increasingly common worldwide public health problem (*Choi et al., 2009*). Chronic hemodialysis is one of the main therapeutic options for end-stage renal disease (ESRD) (*van der Heijden et al., 2004*).

Blood contact with the dialysis membrane has been documented as a major cause of cytokine activation and release. Although haemodialysis-related acute manifestations associated with cytokine release, such as fever and hypotension, are now infrequent; a variety of consequences of chronic low-grade inflammatory state have been recognized or proposed. These include malnutrition, atherosclerosis, cardiovascular disease, erythropoietin-resistant anemia and even a higher mortality rate. Increased cytokine production/ activation may also be responsible for bone remodelling and the aggravation of  $\beta_2$  microglobulin amyloidosis. (*Gill et al., 2007*). By virtue of age, life expectancy and active growth, patients with pediatric-onset ESRD are likely to be more significantly affected by these consequences (*Canaud, 2007*).

Hemodiafiltration (HDF) is a form of renal replacement therapy which combines standard hemodialysis with hemofiltration, a therapy that removes toxins by ultrafiltration of plasma water and uses a replacement fluid to keep the patient in fluid balance (*Whalen, 2008*).

On-line HDF for treatment of ESRD has been introduced into clinical practice in the late 90s. The most important technical and regulatory challenges were the safety and microbiological quality of the substitution/replacement fluid. (*Guth et al., 2003*) This has resulted in the concept of “ultrapure dialyzate” where patient

---

---

contact with endotoxins and other pyrogenic or bacteria-derived substances should be negligible (*Ledebo, 1999*).

Online-HDF may be associated with lower proinflammatory cytokines release than conventional HD.

Tumor necrosis factor (TNF) is the main cytokine associated with endotoxin release, has been implicated in various acute cytokine release syndromes including systemic inflammatory response syndrome (SIRS) and septic shock; and has been reported to be elevated in adults with ESRD on hemodialysis (*Vaslaki et al., 2000*).

## **Aim of the work**

To determine the serum TNF-alpha level in pediatric patients with ESRD undergoing regular hemodialysis;

And to compare TNF levels and dialytic change in TNF between conventional hemodialysis and on-line hemodiafiltration.

## End stage renal disease (ESRD)

### **Definition:**

Chronic kidney disease (CKD) is characterized by an irreversible deterioration of renal function that gradually progresses to end-stage renal disease (ESRD). CKD has emerged as a serious public health problem, as the incidence of the CKD in children has steadily increased (*Levey & Coresh, 2003*).

*Kidney Disease Outcomes Quality Initiative (K/DOQI) working group of the National Kidney Foundation of the United States (2003)* defined CKD as evidence of structural or functional kidney abnormalities (abnormal urinalysis, imaging studies, or histology) that persist for at least three months, with or without a decreased glomerular filtration rate (GFR), as defined by a GFR of less than 60 mL/min per 1.73 m<sup>2</sup>.

### **Incidences and prevalence:**

CKD is frequent, it increases with age, and affects one person out of 10 in the general population, and only 4 per 100,000 will reach end-stage renal disease (ESRD) (*Noël & Landais, 2012*).

The incidence and rate of progression to ESRD are equal in both sexes, although obstructive uropathies are more common in males (*Ardissino et al., 2003*).

## Stages of CKD:

**Table (1): Stages of CKD:**

Stage	Description	GFR	Metabolic consequences
-	At increased risk	Higher than 90 (with risk factors for chronic kidney disease)	-
1	Kidney damage (early) with normal or elevated GFR	90 or higher	-
2	Kidney damage with mildly decreased GFR (early renal insufficiency)	60 to 89	Parathyroid hormone level begins to rise (GFR of 60 to 80).
3	Moderately decreased GFR (moderate kidney failure)	30 to 59	Calcium absorption decreases (GFR below 50).  Lipoprotein activity declines.  Malnutrition develops.  There is onset of left ventricular hypertrophy and/or anemia (erythropoietin deficiency).
4	Severely decreased GFR (pre-end-stage kidney disease)	15 to 29	Triglyceride concentration begins to rise.  Hyperphosphatemia or metabolic acidosis develops.  There is a tendency toward hyperkalemia.
5	Kidney failure (end-stage kidney disease (uremia)	< 15 (or dialysis)	Azotemia develops

*(National Kidney Foundation: K/DOQI, 2003).*

---

Estimation of the GFR gives a rough measure of the number of functioning nephrons. A reduction in GFR implies progression of the underlying disease (*O'Hare et al., 2006*).

The current *K/DOQI guidelines (2003)* state that estimates of GFR is the best overall indices of the level of kidney function. The reference range of GFR in young adults is 120-130 mL/min/1.73 m<sup>2</sup>. However, the reference range of eGFR is much lower in early infancy, even when corrected for body surface area, and subsequently increases in relationship to body size for up to 2 years. Hence, the eGFR ranges that are used to define the 5 CKD stages apply only to children aged 2 years and older (*Hellerstein et al., 2004*).

The eGFR can be estimated from the constant k, plasma creatinine (PCr) (in mg/dL), and body length (L in cm) according to the Schwartz formula, as follows:

$$\text{GFR} = (k \times L) / \text{PCr} \quad (\text{Schwartz et al. 1976}).$$

The value of “k” is different at different ages: k = 0.4 (preterm infants), 0.45 (full-term infants), 0.55 (aged 2-12 y). Therefore, all children with CKD should have an eGFR calculated (*Donadio et al., 2004*).

Cockcroft-Gault another method were used to measure GFR but it is commonly used in adults.

The Creatinine Clearance Rate (CCR)

$$\text{CCR} = \frac{[140 - \text{Age (yr)}] \times \text{weight}}{72}$$

$$\text{S. Creatinine} \times 72 \quad (\text{Michels et al., 2010}).$$